Key clinical point: Final results from the MARIANNE trial revealed similar overall survival times in patients who received trastuzumab emtansine (T-DM1), T-DM1 plus pertuzumab, or trastuzumab plus a taxane (HT).
Major finding: The median overall survival was 50.9 months in the HT arm, 53.7 months in the T-DM1 arm, and 51.8 months in the T-DM1 plus pertuzumab arm.
Study details: Phase 3 trial of 1,095 patients with HER2-positive, advanced breast cancer.
Disclosures: This study was funded by F. Hoffmann–La Roche. The researchers disclosed relationships with Roche and other companies.
Perez EA et al. Cancer. 2019 Jul 18. doi: 10.1002/cncr.32392.